Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Semmelweis University
- License Information
-
More Information
Article History
Received: 23 February 2026
Accepted: 11 May 2026
First Online: 28 May 2026
Declarations
Ethics and consent to participate: Not applicable.
Competing interests: The authors declare that MB, JT, and BH filed an international patent for the combinational treatment of KRAS inhibitors and farnesyl-transferase inhibitors of KRAS mutant cancers (patent number: EP4426303B1).
